Pediatric Rare Disease Voucher Program Faces Expiration
Stakeholders push Congress to renew program, although 21st Century Cures route unlikely.
You may also be interested in...
Chair of the House Energy and Commerce Committee raises questions about the priority review voucher program’s value, suggesting another limited extension may be upcoming.
Next fiscal year will be a good one to redeem a voucher, and probably to qualify for one as well.
It sparked at least one analyst to question how Sarepta came up with a price for FDA's first approved Duchenne muscular dystrophy treatment.